BioArctic, Eisai to present five-year lecanemab data at CTAD 2026

Oct 30, 2026 07:17 (8h ago)

BioArctic and Eisai will present clinical and real-world lecanemab evidence at CTAD 2026 in Boston.
Clarity AD results will cover 60 months of lecanemab treatment, including core and long-term extension phases.
LEADER will report retrospective real-world findings from diverse U.S. clinical settings, while BioArctic presents lecanemab binding research.

BioArctic AB and its partner Eisai will present new clinical and real-world evidence on lecanemab (Leqembi) at the Clinical Trials on Alzheimer's Disease conference in Boston from Nov. 16-19, 2026. The program will include findings through 60 months from the Clarity AD study, analyses from the LEADER retrospective multicenter study of lecanemab use in early Alzheimer's disease across diverse U.S. clinical settings three years after FDA approval, and a BioArctic poster on lecanemab's binding profile. Presentations will also cover real-world safety, including ARIA, treatment persistence, effectiveness, patient experience, biomarker changes, Alzheimer's disease biology and subcutaneous administration. Leqembi is approved in 53 countries and under regulatory review in six countries and regions. The information was released for public disclosure on Oct. 30, 2026, at 08:00 a.m. CET.